Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer

Table 9 Relationship between overall survival and KRAS, BRAF, MEK, and ERK protein expression

	B	SE	Wald	df	Sig.	Exp (B)	95.0%CI of Exp (B)
							Lower limit	Upper limit
KRAS	0.360	0.536	0.452	1	0.501	1.434	0.501	4.101
MEK	-0.736	0.585	1.586	1	0.208	0.479	0.152	1.506
ERK	-0.571	0.501	1.303	1	0.254	0.565	0.212	1.507
BRAF	0.246	0.539	0.208	1	0.648	1.279	0.444	3.680
T			1.733	3	0.630
T1	1.141	1.114	1.050	1	0.306	3.131	0.353	27.776
T2	-0.356	0.696	0.261	1	0.609	0.701	0.179	2.742
T3	0.230	0.562	0.168	1	0.682	1.259	0.418	3.789
N	0.230	0.503	0.209	1	0.647	1.259	0.470	3.373